Synlogic presents at global pku patient meeting

Cambridge, mass., sept. 10, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of investigational synthetic biotic medicines for the treatment of phenylketonuria (pku) at the global pku patient meeting, being held virtually september 10-11 th, 2021.
SYBX Ratings Summary
SYBX Quant Ranking